ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Gains Orphan Drug Status In Japan For CIDP Treatment
Sanofi (ENXTPA:SAN) recently received orphan drug designation from Japan's Ministry of Health for riliprubart, aimed at treating chronic inflammatory demyelinating polyneuropathy. This underscores the company's focus on expanding treatment options for underserved patient populations. Despite this positive development, Sanofi's share price experienced little change in the past week. While the market indices such as the S&P 500 and Nasdaq achieved record highs, bolstered by easing geopolitical...